Serum amyloid A and pairing formyl peptide receptor 2 are expressed in corneas and involved in inflammation-mediated neovascularization

International Journal of Ophthalmology

Volumn 7, Issue 2, 2014, Pages 187-193

  Ren, Sheng Wei ^a,b   Qi, Xia ^b   Wang, Yi Qiang ^b  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b SHANDONG EYE INSTITUTE   (China)

Author keywords

Corneal neovascularization; Formyl peptide receptor; Inflammation; Matrix metallopeptidase; Serum amyloid A

Indexed keywords

EID: 84899810017     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2014.02.01     Document Type: Article

References (57)

1. Ellenberg D, Azar DT, Hallak JA, Tobaigy F, Han KY, Jain S, Zhou Z, Chang JH. Novel aspects of corneal anggenicand lymphanggenic privilege. Prog Retin Eye Res. 20l0;29(3):208-248. [PMCfree article] [PubMed]
2. Qazi Y,Wong G, Monson B, String ham J, Ambati BK. Corneal transparency: genesis, maintenance and dysfunction. Brain Res Bull. 2010;8l(2-3):l98-210. [PMCfreearticle] [PubMed]
3. Clements JL, Dana R. Inflammatory corneal neovascularization: etathogenesis. Semin Ophthalmol. 2011526(4-53:235-245. [PubMed]
4. Jia C, Zhu W, Ren S, Xi H, Li S, Wang Y. Comparison of genome-wide gene expressn in suture-And alkali burn-induced murine corneal neovascularization. Mol Vis. 2011;l7:2386-2399. [PMCfree article] [PubMed]
5. Ren S, Liu T, Jia C, Qi X, Wang Y. Physgical expressn of lens alpha-, beta-, and gamma-cry stallins in murine and human corneas. Mol Vis. 2010;l6:2745-2752. [PMCfree article] [PubMed]
6. Zhu W, Qi X, Ren S, Jia C, Song Z, Wang Y. alphaA-cry stall in in the pathogenesis and intervention of experimental murine corneal neovascularization. Exp Eye Res. 2010598:44-51. [PubMed]
7. Moshkovskii SA. Why docancer cells produce serum amyidA acute-phase protein? Bichemistry (Mosc) 2012;77(4):339-34l. [PubMed]
8. Malle E, Sodin-Semrl S, KovacevicA. Serum amyidA: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci. 2009;66(l):9-26. [PubMed]
9. Ramanku10v A, Lein M, Johannsen M, Schrader M, Miller K, 10ening SA, Jung K. Serum amyid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett. 2008;269(l):85-92. [PubMed]
10. Harr KE, Rember R, Ginn PE, Lightsey J, Keller M, Reid J, Bonde RK. Serum amyidA (SAA) as a bmarker of chronic infection due toboat strike trauma in a free-ranging Frida manatee (Trichechus manatus latirostris) with incidental polycystic kidneys. JWildl Dis. 2011;47(4):1026-103l. [PubMed]
11. Falsey AR, Walsh EE, Francis CW, 10oney RJ, Kolassa JE, Hall WJ, Abraham GN. Response of C-reactive protein and serum amyidA toinfluenza A infection in older adults. J Infect Dis. 2001;l83(7):995-999. [PubMed]
12. Pertovaara M, Jylhava J, Uusita H, Pukander J, Helin H, HurmeM. Serum amyidA and C-reactive protein concentrations are differently associated with markers of autoimmunity in patients with primary Sjogren's syndrome. J Rheumatol. 2009;36(ll):2487-2490. [PubMed]
13. O'Hara R, Murphy EP, WhiteheadAS, FitzGerald O, Bresnihan B. 10cal expressn of the serum amyidA and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalroteinase production in patients with inflammatory arthritis. Arthritis Rheum. 2004;50(6):l788-l799. [PubMed]
14. King VL, Thompson J, Tannock LR. Serum amyidA in atherosclerosis. Curr Opin Lipidol. 2011;22(4):302-307. [PubMed]
15. Kisilevsky R, Tarn SP. Acute phase serum amyidA, cholesterol metabolism, and card10vascular disease. Pediatr Pathol Mol Med. 2002;2l(3):29l-3O5. [PubMed]
16. Lee HY, Kim MK, Park KS, BaeYH, Yun J, Park JI, Kwak JY, Bae YS. Serum amyidA stimulates matrix-metalroteinase-9upregulation via formyl peptide receptor like-l-mediated signaling in human monocytic cells. Bichem Biphys Res Commun. 2005;33o(3):989-998. [PubMed]
17. Bjorkman L, Karlsson J, Karlsson A, Rabier MJ, Boulary F, Fu H, Bylund J, Dahlgren C. Serum amyidA mediates human neutrophil production of reactive oxygen species through a receptor independent of formyl peptide receptor like-l. JLeukocBil. 2008;83(2):245-253. [PubMed]
18. Mullan RH, McCormick J, Conny M, Bresnihan B, Veale DJ, Fearon U. A role for the high-density lipoprotein receptor SR-Bl in synovial inflammation via serum amyid-A. Am J Pathol. 2010;176(4):1999-2008. [PMCfree article] [PubMed]
19. Baranova IN, Bocharov AV, Vishnyakova TG, Kurlander R, Chen Z, Fu D, Arias IM, CsakoG, Patterson A, Eggerman TL. CD36is a novel serum amyidA (SAA) receptor mediating SAA binding and SAA-induced signaling in human and rodent cells. JBil Chem. 2010;285(ll):8492-8506. [PMCfree article] [PubMed]
20. Baranova IN, Vishnyakova TG, Bocharov AV, Kurlander R, Chen Z, Kimelman ML, Remaley AT, CsakoG, Thomas F, Eggerman TL, Patterson A. Serum amyidA binding toCLA-l (CD36 and LIMPII ana gous-l) mediates serum amyidA protein-induced activation of ERK1/2 and P38 mitogen-Activated protein kinases. J Bil Chem. 2005;28o(9):8o3l-8o40. [PubMed]
21. Cheng N, He R, Tian J, Ye PP, Ye RD. Cutting edge:TLR2 is a functional receptor for acute-phase serum amyidA. J Immunol. 2008;l8l(l):22-26. [PMCfreearticle] [PubMed]
22. Sandri S, Rodriguez D, Gomes E, MonteiroHP, RussoM, Cam pa A. Is serum amyidA an endogenous TLR4 agonist? J LeukocBil. 2008;83(5):ll74-ll8o. [PubMed]
23. Niemi K, Teirila L, Lappalainen J, Rajamaki K, Baumann MH, Oorni K, Wolff H, Kovanen PT, Matikainen S, EklundKK. Serum amyidA activates the NLRP3 i nfl am m asom e via P 2X7 receptor and a cathepsin B-sen si tive pathway. J Immunol. 2011;l86(ll):6ll9-6l28. [PubMed]
24. Zou Y, Zhang H, Li H, Chen H, Song W, Wang Y. Strain-dependent production of interleukin-17/interferon-gamma am matrix remodeling-Associated genes in experimental Candida albicans keratitis. Mol Vis. 2012;l8:l2l5-l225. [PMCfree article] [PubMed]
25. Gordon GM, Austin JS, Sklar AL, Feuer WJ, LaGier AJ, Fini ME. Comprehensive gene expressn profiling and functional analysis of matrix metal roteinases andTIMPs, and identification of ADAM-10 gene expressn, in a cornea model of epithelial resurfacing. J Cell Phys. 2011;226(6) 11461-1470. [PubMed]
26. Wang Y, Wang C, Jia C, Ren S, Yang L. Gene Expressn profiling in murine corneal neovascularization models. GSE23347. 2011 http://www.ncbi.nlm.gov/geo.
27. Steel DM, WhiteheadAS. The major acute phase reactants: C-reactive protein, serum amyid P component and serum amyidA protein. Immunol Today. l994;l5(2):8l-88. [PubMed]
28. Pizzini C, Mussap M, Plebani M, Fanos V. C-reactive protein andserum amyidA protein in neonatal infections. Scand JInfect Dis. 200032(3):229-235. [PubMed]
29. Wilson PG, Thompson JC, Webb NR, de Beer FC, King VL, Tan nock LR. Serum amyidA, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-Atherogenic manner. Am J Pathol. 2008;173(6):1902-191O. [PMCfree article] [PubMed]
30. Knebel FH, Albuquerque RC, MassaroRR, Maria-Engler SS, Campa A. Dual effect of serum amyidA on the invasiveness of glma cells. Mediators Inflamm. 201352013:509089. [PMCfree article] [PubMed]
31. ez-Campos JL, CaleroC, RojanoB, ez-Porras M, Saenz-Coronilla J, BlancoAI, Sanchez-ez V, Tobar D, Montes-Worboys A, ArellanoE. C-reactive protein andserum amyid a overexpressn in lung tissues of chronic obstructive pulmonary disease patients: a case-control study. Int J Med Sci. 2013;10(8):938-947. [PMCfree article] [PubMed]
32. Matsui S, YamaneT, Kobayashi-Hattori K, Oishi Y. Calcitonin Gene-Related Peptide Upregulates Serum AmyidA Synthesis through Activation of Interleukin-6. Bisci Bitechnol Bichem. 2013;77(10):2151-2153. [PubMed]
33. Uriel i-Sh oval S, LinkeRP, MatznerY. Expressn and function of serum amyidA, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 200057(1):64-69. [PubMed]
34. ReigstadCS, Backhed F. Microbial regulation of SAA3 expressn in mouse con and adipose tissue. Gut Microbes. 2010;l(l):55-57. [PMCfree article] [PubMed]
35. Kluve-Beckerman B, Drumm ML, Benson MD. Nonexpressn of the human serum amyidA three (SAA3) gene. DNA Cell Bil. 199i;10(9):65l-66l. [PubMed]
36. Soler L, Luyten T, Stinckens A, Buys N, Ceron JJ, NiewoldTA. Serum amyid A3 (SAA3), not SAAl appears to be the major acute phase SAA isoform in the pig. Vet Immunol Immunopathol. 20115141 (1-2):l09-115. [PubMed]
37. Geurts J, Vermeij EA, Pohlers D, Arntz CJ, KinneRW, van den Berg WB, van de 10o FA. A novel Saa3-promoter reporter distinguishes inflammatory subtypes in experimental arthritis andhuman synovial fibroblasts. Ann Rheum Dis. 2011;7O(7):l3ll-l3l9. [PubMed]
38. deBeer MC, de Beer FC, Gerardot CJ, Cecil DR, Webb NR, Goodson ML, Kindy MS. Structure of the mouse Saa4 gene and its linkage to the serum amyidA gene family. Genomics. 1996;34(l):l39-142. [PubMed]
39. deBeer MC, Yuan T, Kindy MS, Aszta s BF, Roheim PS, deBeer FC. Characterization of constitutive human serum amyidA protein (SAA4) as an apolipoprotein. JLipidRes. 1995;36(3):526-534. [PubMed]
40. He R, Sang H, Ye RD. Serum amyidA induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Biod. 2003;l0l(4):l572-l58l. [PubMed]
41. Su SB, Gong W, Gao JL, Shen W, Murphy PM, Oppenheim JJ, Wang JM. A seven-transmembrane, Gprotein-coupled receptor, FPRLl, mediates the ch em otactic activity of serum amyid A for human phagocytic cells. J Exp Med. 1999;l89(2):395-402. [PMCfreearticle] [PubMed]
42. Cai L, de Beer MC, de Beer FC, van der Westhuyzen DR. Serum amyidA is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding andselectivelipid uptake. JBil Chem. 20055280(4) 12954-2961. [PubMed]
43. La vie M, Voisset C, Vu-Dac N, Zurawski V, Duverlie G, Wychowski C, Dubuisson J. Serum amyidA has antiviral activity against hepatitis Cvirus by inhibiting virus entry in a cell culture system. Hepatogy. 2006;44(6):l626-l634. [PubMed]
44. He RL, Zhou J, Hanson CZ, Chen J, Cheng N, Ye RD. Serum amyidA induces G-CSFexpressn and neutrophilia via T011-like receptor 2. Biod. 2009;ll3(2):429-437. [PMCfree article] [PubMed]
45. Ather JL, Ckless K, Martin R, Foley KL, Suratt BT, Boyson JE, Fitzgerald KA, Flavell RA, Eisenbarth SC, Poynter ME. Serum amyidA activates the NLRP3 inflammasome and promotes Th 17 allergic asthma in mice. J Immunol. 2011;l87(l):64-73. [PMCfree article] [PubMed]
46. ChoK, Pham TN, Crivel SD, Jeong J, Green TL, Greenhalgh DG. Involvement of CD14 andt011-like receptor 4 in the acute phase response of serum amyidA proteins and serum amyid P component in the liver after burn injury. Shock. 2004;2l(2):l44-l50. [PubMed]
47. TamamotoT, OhnoK, Goto-KoshinoY, TsujimotoH. Feline serum amyidA protein as an endogenous T011-like receptor 4 agonist. Vet Immunol Immunopathol. 2013;l55(3):l90-l96. [PubMed]
48. de Seny D, CobraivilleG, Charlier E, Neuville S, Esser N, Malaise D, Malaise O, CalvoFQ, Relic B, Malaise MG. Acute-phase serum amyid a in osteoarthritis: regulatory mechanism andproinflammatory properties. P S One. 2013;8(6):e66769. [PMCfree article] [PubMed]
49. Christenson K, Bjorkman L, TangemoC, BylundJ. Serum amyidA inhibits apoptosis of human neutrophils via a P2X7-sensitive pathway independent of formyl peptide receptor-like 1. JLeukocBil. 2008583(1) 1139-148. [PubMed]
50. Mull an RH, Bresnihan B, Golden-Mason L, Markham T, O'Hara R, FitzGeraldO, Veale DJ, Fearon U. Acute-phase serum amyidA stimulation of a nggenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum. 2006554(1) 1105-114. [PubMed]
51. Conny M, Mull an RH, McCormick J, Matthews C, Sullivan O, Kennedy A, FitzGeraldO, PooleAR, Bresnihan B, Veale DJ, Fearon U. Acute-phase serum amyidA regulates tumor necrosis factor alpha and matrix turnover and predicts disease progressn in patients with inflammatory arthritis before and after bgic therapy. Arthritis Rheum. 2012;64(4):1035-1045. [PubMed]
52. Migita K, KawabeY,Tominaga M, Origuchi T,Aoyagi T, Eguchi K. Serum amyidA protein induces production of matrix metalroteinases by human synovial fibroblasts. Lab Invest. 1998;78(5):535-539. [PubMed]
53. ZhaoY, Zhou S, Heng CK. Celecoxib inhibits serum amyida-inducedmatrix metalroteinase-10 expressn in human endothelial cells. J Vase Res. 2009;46(l):64-72. [PubMed]
54. Upragarin N, Landman WJ, Gaastra W, Gruys E. Extra hepatic production of a cute phase serum amyidA. Histol Histopathol. 2005;20(4):1295-13O7. [PubMed]
55. Conny M, Marrelli A, Blades M, McCormick J, Maderna P, Godson C, Mullan R, FitzGeraldO, Bresnihan B, Pitzalis C, Veale DJ, Fearon U. Acute serum amyidA induces migration, anggenesis, and inflammation in synovial cells in vitro andinahuman rheumatoid arthritis/SCIDmouse chimera model. J Immunol. 20105184(11) 16427-6437. [PubMed]
56. Cai X, Freedman SB, Witting PK. Serum amyidA stimulates cultured endothelial cells to migrate and proliferate: inhibition by the multikinase inhibitor BIBF1120. Clin Exp Pharmacol Phys. 2013;40(9):662-67O. [PubMed]
57. Lakota K, Mrak-Poljsak K, Rozman B, Sodin-Semrl S. Serum amyidA and its potential physgical/pathogical function s-An overview of patents. Recent Pat Endoocr Metab & Immune Drug Discov. 201054:89-99.